** Amgen AMGN.O shares little changed at $288.82 ahead of Q4 earnings due after the closing bell
** The biotech company is expected to post EPS of $5.08 per share, compared with $4.71 a year ago, on revenue of $8.88 bln, per LSEG data, vs yr-ago results of and $8.2 bln in revenue
** AMGN has met or beat EPS expectations in 6 of past 8 qtrs, with most recent miss in Q2 2024
** Of the 33 analysts that cover Amgen Inc, the breakdown of recommendations are 16 "strong buy" or "buy," 14 "hold" and 3 "sell" or "strong sell" ratings
** Median price target of $316 is down from $331.50 a month ago
** AMGN shares up 10.7% YTD vs 4.8% gain in Dow Industrials .DJI
** AMGN options imply a 4.4% swing for the shares, in either direction, by Fri, in line with the stock's 8-qtr avg 1-day move after results, according to according to Trade Alert
(Reporting by Chuck Mikolajczak, additional reporting by Saqib Ahmed)
((charles.mikolajczak@tr.com; @ChuckMik;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.